Quality of life is often considered when deciding and evaluating the treatment strategy for patients diagnosed with anal fistula.
lieved to arise as a result of a cryptoglandular infection and are more frequent among adults between 30 and 60 years of age. 2, 3 Although the actual incidence of AF remains unknown, and there is high geographic variability reported in the literature (from 0.86 per 10,000 per year in Helsinki to 2.32 per 10,000/year in Italy), this is generally considered an uncommon disease. 3, 4 Nonetheless, the management of AFs is often the focus in international literature on coloproctology. The symptomatology most frequently associated with an AF includes suppuration, bleeding, and/or pain, which are often preceded by the drainage of a perianal abscess and can severely affect patient quality of life (QoL). 2, 5, 6 The curative treatment for AFs can be costly and always requires a surgical intervention. 3, 7, 8 Indeed, it is suggested that between 10% and 30% of the total surgical procedures performed by coloproctology specialists could be related to the management of AFs. 7 Although the aim of undertaking surgery on these patients is clearly directed toward removing the fistula, alleviating its symptoms, preventing its recurrence, and preserving the sphincter function, its effectiveness can be variable. 7 For example, in patients presented with noncomplex, primary fistulas (ie, intersphicteric and low transsphincteric), fistulotomy is usually the surgical procedure of choice and is believed to be useful in ≈90% of the cases. 7, 9, 10 However, in patients presenting with complex AFs, the results from performing different surgical procedures (ie, mucosal advancement flap, seton placement, ligation of intersphincteric fistula tract procedure, plugs, and adhesives) remain unclear and are somewhat controversial. [11] [12] [13] [14] Consequently, a risk of recurrence of ≈10% to 60% and complications such as incontinence attributed to undergoing numerous unsuccessful surgical interventions can also contribute to negatively affect patient QoL. 4, [13] [14] [15] In the light of this, patient QoL emerges as an important indicator that is often taken into consideration by coloproctology specialists when making individualized decisions on the treatment strategy to be followed for each patient and the posterior evaluation of its success. [16] [17] [18] [19] [20] [21] However, to the best of our knowledge, no instrument to specifically assess QoL in patients diagnosed with AF has been developed, validated, and published. In fact, our literature review evidenced that the tools used to evaluate QoL among patients diagnosed with AF were initially designed for measuring either general health-related QoL (Short Form 12 Health Survey (SF-12) and Short Form 36 Health Survey) [16] [17] [18] [19] or other constructs related to patient incontinence (St. Mark's incontinence score, Cleveland incontinence score, Wexner score, and Fecal Incontinence Quality of Life scale). [16] [17] [18] [19] [20] [21] In this context, the design of a valid and reliable instrument that aims to evaluate QoL among patients with AF could help to provide more specific and better-fitted information about this particular population. The aim of this study was to develop and evaluate the psychometric properties of a questionnaire to assess QoL in patients diagnosed with AF.
PATIENTS AND METHODS

Study Design and Participants
In this study, an observational cross-sectional design was used for the development and validation of the Quality of Life in Patients with Anal Fistula Questionnaire (QoLAF-Q). Following a convenience sampling technique, patients attending the coloproctology clinic in a general hospital in the southeast of Spain between March 2015 and June 2016 were recruited for the study. The inclusion criteria for participation were age ≥18 years and diagnosis with a cryptoglandular AF. The exclusion criteria for participation were as follows: 1) experiencing any cognitive impairment that could interfere with understanding and completing the questionnaire, 2) experiencing IBD or any other medical condition that could affect QoL (ie, chronic obstructive pulmonary disease or fibromyalgia), and 3) presenting with an AF secondary to carcinoma, radiation therapy, obstetric damage, or any other primary cause that could affect QoL. Eighty participants were eligible for inclusion, and 54 volunteered to participate. Patient demographic characteristics, past medical history, and information about the AF were collected.
Ethical Considerations
The institutional ethics in research board granted ethical approval. Patients meeting the eligibility criteria were invited to participate in the study by their surgeon and received a written document with information about their rights, the study aim, and the research plan. Patients who volunteered to participate signed an informed consent form before enrolling in the study. All of the data collected were treated in accordance with the European legislation on data protection.
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Initial Development of the Questionnaire
The researchers developed the QoLAF-Q based on their experiences with patients, the most frequent clinical manifestations of AFs, 2 and the domains included in the World Health Organization Quality of Life assessment. 23 The initial version of the QoLAF-Q (i-QoLAF-Q) was developed in Spanish and composed of 17 items, with response options that followed a 5-point Likert-type format.
Before its administration to the study participants, the i-QoLAF-Q was critically revised by a panel of 14 independent experts in coloproctology and colorectal surgery from different institutions. To calculate the content validity index (CVI) of the i-QoLAF-Q, these experts were requested to score each item (1 = not relevant; 2 = somewhat relevant; 3= quite relevant; or 4 = highly relevant) for measuring QoL in patients diagnosed with AF. 24 The CVI for each individual item (I-CVI) was estimated by summing the number of experts rating the item as either quite relevant or highly relevant and dividing it by the total number of experts in the panel. 24 For a panel of 14 experts, an I-CVI ≥ 0.78 was considered acceptable because it showed a high degree of agreement about its relevance. 24 Table 1 shows that the experts considered items 3, 4, and 16 not to be relevant for measuring QoL in patients diagnosed with AF (I-CVI < 0.78), and these were removed from the Qo-LAF-Q (see Appendix 1, http://links.lww.com/DCR/A396, for additional information on the questions and response options for the QoLAF-Q).
Data Analysis of the Final Version of the QoLAF-Q The 14-item version of the QoLAF-Q was tested among the study sample and psychometrically evaluated following the guidelines and recommendations of other authors. [24] [25] [26] [27] [28] The QoLAF-Q was originally developed and tested in Spanish. The forward-backward translation procedure recommended by the European Organisation for Research and Treatment of Cancer was used to translate the QoLAF-Q to English. 29 IBM SPSS version 21 (IBM Corp, Armonk, NY) was used to perform the data analysis.
Readability and Understandability
The readability and grade level of the QoLAF-Q were assessed using the Flesch-Kincaid tool in Microsoft Word (Microsoft, Redmond, WA). To evaluate its understandability, 10 independent native Spanish speakers and 5 independent nonnative, nonproficient Spanish speakers were asked to comment on the difficulties that they might have found when reading and completing the QoLAF-Q. Using feedback from nonnative, nonproficient Spanish speakers can give directions to further simplify the readability of the tool and improve its understandability. 25, 26 The completion time for the instrument was recorded.
Reliability
To evaluate the reliability of the QoLAF-Q, its internal consistency and temporal stability were investigated. The internal consistency of the QoLAF-Q was evaluated using the following 3 estimators: 1) the Cronbach coefficient α for the overall tool, 2) the estimated Cronbach α of the overall tool if a particular item was removed, and 3) the corrected item total correlation (C-ITC). Items were considered to positively contribute to increase the internal consistency of the QoLAF-Q if the corrected C-ITC of the item was >0.3, and the Cronbach α coefficient of the tool did not significantly increase after removing that particular item. To assess the temporal stability of the QoLAF-Q, participants completed the questionnaire on 2 occasions separated by a 4-week interval using an identical data collection procedure for the test and retest. The Spearman correlation coefficient (r) and weighted Cohen κ were cal- culated. In this 4-week interval, participants underwent additional diagnostic tests and did not receive any treatment; they were recommended to maintain good hygiene of the perianal area.
Validity
The content, criterion, and construct validity of the QoLAF-Q were examined. For the assessment of the content validity of the QoLAF-Q, the average CVI of the overall questionnaire (S-CVI/Ave) was calculated; the data obtained from the critical review procedure performed by the aforementioned panel of experts were used for the calculation. A S-CVI/Ave >0.90 was considered as evidence of the content validity of the instrument. 24 For the assessment of the QoLAF-Q criterion validity, its concurrent validity was studied, and the SF-12 was used as the criterion of reference for comparisons. 30 The decision to use the SF-12 for comparisons was based on the following criteria: 1) it measures all of the domains composing the construct health-related QoL, 23, 30 2) it is a widely used instrument that has shown excellent psychometric properties in its Spanish version, 30 and 3) it is short, easy to understand, and simple to complete by the participants. The Spearman correlation coefficient (r) between patient results on the QoLAF-Q and results on the Spanish version of the SF-12 was calculated. In addition, we conducted an ordinal logistic regression analysis in which the associations between participant scores in the QoLAF-Q and the SF-12 were explored. Lastly, for the assessment of the QoLAF-Q construct validity, principal component analysis (PCA) and known-groups analysis were performed.
Principal Component Analysis
This analysis aimed to identify the principal components of the QoLAF-Q and the items that should be retained as part of the instrument. Before investigating the structure of the QoLAF-Q, the appropriateness to perform PCA was tested by carrying out the Kaiser-Meyer-Olkin measure of sampling adequacy and the Bartlett test of sphericity. Then, an unlimited factor analysis test with varimax rotation was computed. Factors were retained as part of the QoLAF-Q if they met the following criteria: 1) factor eigenvalues ≥1, 2) presence of a clear graphic representation of the factor on the plot of eigenvalues, and 3) item factorloading value ≥0.45. 
Known-Group Analysis
The total sample (N = 54) was divided in groups depending on the participant scores on the following clinical manifestations: frequency of suppuration, amount of suppuration, frequency of pain, and intensity of pain. Based on this categorization, between-group differences in individual QoLAF-Q scores were expected, and the KruskalWallis H test was carried out to explore them.
Development of a Scoring and Interpretation
System for the QoLAF-Q Participant score on the QoLAF-Q could range from 14 (minimum score) to 70 (maximum score). Using a summation method, 32 the following 5-category scoring and interpretation system was developed: zero impact = 14 points, limited impact = 15 to 28 points, moderate impact = 29 to 42 points, high impact = 43 to 56 points, and very high impact = 57 to 70 points.
A panel of 20 experts was asked to score their degree of agreement with the appropriateness and usefulness of the aforementioned scoring and interpretation system using a 5-point Likert scale (1 = strongly agree, 2 = agree, 3 = neither agree or disagree, 4 = disagree, 5 = strongly disagree). Furthermore, the experts were asked to provide any feedback that they considered appropriate about the scoring and interpretation system proposed by the researchers.
RESULTS
There were no missing values in the data set used in this study.
Description of the Main Sample
The mean age of the main sample was 46.7 years (SD = 11.60 y; range, 24-70 y), and 74.1% of participants were men. Table 2 presents detailed information about patient demographics, past medical history, and specific characteristics of their AF.
Readability and Understandability
The reading level of the QoLAF-Q corresponds with fourth grade, so it can be read by a schooled 10-year-old individual. Neither the independent native Spanish speakers nor the independent nonnative, nonproficient Spanish speakers reported any difficulties when reading and completing the QoLAF-Q. Furthermore, mean completion time was <5 minutes (range, 4-6 min). Table 1 presents detailed results of the internal consistency analysis for the QoLAF-Q (N = 54). The QoLAF-Q Cronbach α equals 0.908, which would not have significantly increased after removing any of the items. The C-ITC for the items ranged from 0.35 to 0.83. Regarding the analysis of the temporal stability of the tool, the Spearman correlation coefficient between the test and the 4-week retest was very high (r = 0.861; p < 0.001). In addition, the weighted Cohen κ was very good when unequal distance between the response options was as-sumed (quadratic κ = 0.82 (95% CI, 0.735-0.906)) and good when equal distance between the response options was assumed (linear κ = 0.72 (95% CI, 0.593-0.847); see Table 3 ).
Reliability
Validity
Regarding content validity, the I-CVI for the 14 items composing the QoLAF-Q ranged from 0.79 to 1.00 (see Table 1 ) and the QoLAF-Q S-CVI/Ave was 0.92. In terms of concurrent validity, the QoLAF-Q showed a strong, significant correlation with the SF-12 (r = 0.734; p < 0.001). Moreover, ordinal logistic regression analysis suggested that participant scores on the QoLAF-Q explained ≈46.2% of the between-subject variation for the participant scores on the SF-12 (Nagelkerke R 2 = 0.462). However, those patients in whom the AF has a limited or moderate impact over their QoL (based on their scores on the QoLAF-Q) had statistically significant higher odds of scoring among the groups with worse health-related QoL (based on their results on the SF-12), with an OR of 0.020 (95% CI, 0.04-0.95) and an OR of 0.124 (95% CI, 0.032-0.485; see Table 4 for a summary of the interactions between participant results on the SF-12 and the QoLAF-Q).
Results for construct validity analysis are presented below.
Principal Component Analysis
The Bartlett test of sphericity was significant (χ 2 = 450.32; p < 0.01), and the Kaiser-Meyer-Olkin measure of sampling adequacy was 0.764; thus, PCA was carried out. Table 5 presents the results of the PCA on the 14-item QoLAF-Q. Two factors showed eigenvalues of ≥1, a clear graphic representation on the plot of eigenvalues, and all of their loading items with a factor-loading coefficient of ≥0.45. These two factors accounted for 81.63% of the total variance found and refer to the physical (factor 1) and biopsychosocial (factor 2) impact of the AF (see Table 5 ).
Known-Groups Analysis
Known-groups analysis results are shown in Table 6 . In summary, the Kruskal-Wallis H test showed that the participant scores on the total QoLAF-Q and its 2 subscales are significantly different (p < 0.05) depending on their self-reported frequency of suppuration, amount of suppuration, frequency of pain, and intensity of pain.
Scoring and Interpretation System for the QoLAF-Q
The 20 experts revising the scoring and interpretation system proposed by the researchers either strongly agreed (n = 17) or agreed (n = 3) with its appropriateness. No additional changes were required.
DISCUSSION
Our literature review suggested that QoL is an essential indicator to be taken into consideration when deciding the strategy to be followed in the treatment of patients diagnosed with AF. [14] [15] [16] [17] [18] [19] [20] [21] However, previously published studies exploring QoL among these patients have always used instruments that were initially designed for the evaluation of QoL of more generic populations. [16] [17] [18] [19] [20] [21] To the best of our The physical anamnesis, digital rectal examination, and injection of hydrogen peroxide were performed during the patient's visit to the outpatient coloproctology clinic.
b
The MRI and anoscopy were requested in order to confirm diagnosis of the anal fistula and determine its classification after the first visit to the outpatient coloproctology clinic.
knowledge, no specific tools for the assessment of QoL in patients with AF have been previously designed, validated, and published, hence why this study aimed to develop and evaluate the psychometric properties of the QoLAF-Q. The psychometric evaluation of the QoLAF-Q intended to find an evidence-based answer to the following 3 questions: 1) does the tool measure accurately, 2) what does the tool actually measure, and 3) is the tool actually usable? Although questions 1 and 2 refer to the reliability and validity of the QoLAF-Q, question 3 concerns the tool's readability, understandability, and applicability. 27, 28 Regarding the first question, the psychometric analysis performed demonstrated the excellent internal consistency and temporal stability of the QoLAF-Q among the study sample. These qualities could be considered proof of the tool's reliability, repeatability, and reproducibility. 27, 28 To answer the second question, content, criterion, and construct validity of the QoLAF-Q were explored. First, the QoLAF-Q content validity analysis included a process of critical review by a panel of 14 experts and evidenced that all of the items included in the final 14-item version of the QoLAF-Q contributed to the operationalization of QoL in patients with AF as a measurable concept. 24, 27, 28 Second, in relation to criterion validity, the concurrent validity of QoLAF-Q was assessed by exploring its ability to correlate and converge with patient score on the SF-12, which measures the health-related QoL of individuals. Evidence has shown that the QoLAF-Q not only correlates very strongly with this previously validated and widely used tool but is also able to make similar decisions about patient QoL. These results could be interpreted as an indicator of the ability of QoLAF-Q to provide valid information about the QoL of patients diagnosed with AF. 27, 28 Furthermore, regarding the construct validity of the tool, evidence from the PCA suggests that the QoLAF-Q has 2 clearly defined subscales, which evaluate the extent to which the AF impacts the patient's physical and biopsychosocial domains of QoL. Corroborating the confirmatory evidence of the construct Impact of the anal fistula on the patient QoL was categorized according to the scoring system proposed in this article.
validity of the instrument results from the knowngroup analysis showed the ability of the QoLAF-Q to detect expected differences between individuals depending on their symptomatology. Finally, concerning the usability of the instrument, results have shown that the QoLAF-Q is an easily understandable and applicable tool that can be completed in <5 minutes and provide immediate information about the impact that the AF has on patient QoL.
Although the QoLAF-Q could be used in research (eg, experimental designs comparing the efficacy of different treatment approaches on patient QoL) and in clinical practice (eg, as part of the initial assessment of patients with AF), some limitations must be highlighted. First, the small size of the main sample, which could have affected the validity of our PCA and known-groups analysis, together with the use of a convenience sampling method, does not allow for the generalization of the results. Because the participants were a relatively small group of patients with specific characteristics (eg, all of the patients presented with a cryptoglandular AF and the majority were men), those willing to use the QoLAF-Q among different populations should conduct a validation study before doing so. Second, although the participants were encouraged to make comments on how they would improve the QoLAF-Q once they had completed it, this study did not include them in the discussion that led to the initial development of the questionnaire. We suggest that future validation and adaptation studies of the QoLAF-Q conduct in-depth interviews and/or focus groups in which patients have the opportunity to be more actively involved with the process of deciding which items are included in the questionnaire and how these items are worded. Third, our scoring system for the QoLAF-Q does not take into account that some items may be more important than others for measuring the underlying construct and may potentially lead to a cancellation effect. 32 We recommend that future studies develop scoring systems using other approaches and compare them with the one presented in this article. Finally, because the QoLAF-Q was created and psychometrically tested in Spanish, its use in other languages must be preceded by an appropriate translation and validation process.
CONCLUSION
The QoLAF-Q has shown excellent psychometric properties after being subjected to a rigorous testing process. The QoLAF-Q has proven to be a valid, reliable, and concise tool that could contribute to the evaluation of QoL among patients with AF. In addition, its easy and rapid applicability could facilitate its use and contribute to informing the physician in the decision-making process in which the most suitable treatment for each particular case is usually discussed. It is suggested that future studies focus on assessing the psychometric properties of the QoLAF-Q after translating it into different languages and validating its usability on larger randomized samples of patients. Known-groups categorization was made on the basis of participants' self-reported suppuration (frequency and amount) and pain (frequency and intensity).
QoLAF-Q = Quality of Life in Patients With Anal Fistula Questionnaire.
a Between-groups differences were analyzed using Kruskal-Wallis H test.
Significance level is shown when p ≤ 0.05.
